SCHEMBL8146643

SCHEMBL8146643

Bc1nc(N)sc1C(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.48
PKM P14618 3/20 0.48
ALDH1A1 P00352 9/20 0.46
HSD17B10 Q99714 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HPGD P15428 3/20 0.46
GAA P10253 3/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
CYP1A2 P05177 1/20 0.44
MAPT P10636 4/20 0.42
KMT2A Q03164 2/20 0.42
GLA P06280 2/20 0.42
MEN1 O00255 1/20 0.42
ALOX15 P16050 1/20 0.42
ATM Q13315 1/20 0.42
TSHR P16473 1/20 0.42
RCE1 Q9Y256 2/20 0.42
CASP1 P29466 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL276275 0.79 ALDH1A1 (0.62) KDM4EPKMALDH1A1HPGDGAA
SCHEMBL8149166 0.79 TRPM8 (0.45) KDM4EPKMALDH1A1HSD17B10SMN1; SMN2
SCHEMBL12670519 0.79 TRPM8 (0.45) KDM4EPKMALDH1A1HSD17B10SMN1; SMN2
SCHEMBL8574686 0.78 KDM4E (0.48) KDM4EPKMALDH1A1HSD17B10SMN1; SMN2
SCHEMBL2444986 0.76 ALDH1A1 (0.50) KDM4EPKMALDH1A1HSD17B10SMN1; SMN2
SCHEMBL1552673 0.76 ALDH1A1 (0.54) KDM4EPKMALDH1A1HSD17B10SMN1; SMN2
SCHEMBL8071199 0.76 ALDH1A1 (0.55) KDM4EPKMALDH1A1HSD17B10SMN1; SMN2
SCHEMBL1540028 0.75 ALDH1A1 (0.49) KDM4EPKMALDH1A1HSD17B10SMN1; SMN2
SCHEMBL12677142 0.75 L3MBTL1 (0.42) KDM4EPKMALDH1A1HSD17B10SMN1; SMN2
SCHEMBL2441749 0.75 KDM4E (0.42) KDM4EPKMALDH1A1HSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 US disclosed
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-02 US disclosed
WO-2008139416-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222328-A1 2-CYCLOPROPYL-THIAZOLE DERIVATIVES HCRTR2, HCRTR1, NPY2R KDM4E 2641/4885PKM 2202/4885ALDH1A1 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.